Published in N Engl J Med on September 30, 1993
Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc (1995) 2.67
Toxoplasma evacuoles: a two-step process of secretion and fusion forms the parasitophorous vacuole. EMBO J (2001) 2.62
A plastid segregation defect in the protozoan parasite Toxoplasma gondii. EMBO J (2001) 2.37
Transepithelial migration of Toxoplasma gondii is linked to parasite motility and virulence. J Exp Med (2002) 2.09
Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J Clin Microbiol (2005) 1.78
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76
Epigenomic modifications predict active promoters and gene structure in Toxoplasma gondii. PLoS Pathog (2007) 1.69
Screening for Toxoplasma gondii-regulated transcriptional responses in lipopolysaccharide-activated macrophages. Infect Immun (2006) 1.67
In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother (1995) 1.60
A novel polymer of tubulin forms the conoid of Toxoplasma gondii. J Cell Biol (2002) 1.56
Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev (2001) 1.54
Antiparasitic agent atovaquone. Antimicrob Agents Chemother (2002) 1.41
Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol (1995) 1.39
Toxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase. Eukaryot Cell (2002) 1.31
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother (1997) 1.30
Genetic approaches to studying virulence and pathogenesis in Toxoplasma gondii. Philos Trans R Soc Lond B Biol Sci (2002) 1.21
Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infect Immun (2002) 1.19
Host but not parasite cholesterol controls Toxoplasma cell entry by modulating organelle discharge. Mol Biol Cell (2003) 1.18
Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases acute virulence in mice. Infect Immun (1998) 1.09
Toxoplasma gondii acyl-lipid metabolism: de novo synthesis from apicoplast-generated fatty acids versus scavenging of host cell precursors. Biochem J (2006) 1.02
Temporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivo. Infect Immun (2008) 1.02
The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. Parasitology (2014) 1.01
Azithromycin for ocular toxoplasmosis. Br J Ophthalmol (1998) 1.00
Differences in iNOS and arginase expression and activity in the macrophages of rats are responsible for the resistance against T. gondii infection. PLoS One (2012) 0.99
Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy. Curr Infect Dis Rep (2000) 0.96
Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. Antimicrob Agents Chemother (2002) 0.96
Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother (1996) 0.96
Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin. PLoS Pathog (2013) 0.95
Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother (1996) 0.95
Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect (1998) 0.95
Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Antimicrob Agents Chemother (1996) 0.91
Hammondia hammondi, an avirulent relative of Toxoplasma gondii, has functional orthologs of known T. gondii virulence genes. Proc Natl Acad Sci U S A (2013) 0.90
TgICMAP1 is a novel microtubule binding protein in Toxoplasma gondii. PLoS One (2009) 0.90
Protein binding of clindamycin in sera of patients with AIDS. Antimicrob Agents Chemother (1996) 0.89
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans. PLoS One (2015) 0.89
CD8 T Cells and Toxoplasma gondii: A New Paradigm. J Parasitol Res (2011) 0.88
Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol (2012) 0.88
Novel thioredoxin-like proteins are components of a protein complex coating the cortical microtubules of Toxoplasma gondii. Eukaryot Cell (2013) 0.87
Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin. Int Ophthalmol (2008) 0.87
Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV AIDS (Auckl) (2011) 0.87
In vitro investigation of host resistance to Toxoplasma gondii infection in microglia of BALB/c and CBA/Ca mice. Infect Immun (2001) 0.86
Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis. BMC Infect Dis (2013) 0.85
Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev (1995) 0.84
Toxoplasma gondii down modulates cadherin expression in skeletal muscle cells inhibiting myogenesis. BMC Microbiol (2011) 0.83
Toxoplasma gondii and the blood-brain barrier. Virulence (2012) 0.82
Current indications for the use of clindamycin: A critical review. Can J Infect Dis (1998) 0.82
Elevated Toxoplasma gondii Infection Rates for Retinas from Eye Banks, Southern Brazil. Emerg Infect Dis (2016) 0.81
Toxoplasmosis in Mexico: epidemiological situation in humans and animals. Rev Inst Med Trop Sao Paulo (2015) 0.81
An ensemble of specifically targeted proteins stabilizes cortical microtubules in the human parasite Toxoplasma gondii. Mol Biol Cell (2015) 0.81
Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy. J Neurol Neurosurg Psychiatry (1998) 0.81
Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro. Antimicrob Agents Chemother (2002) 0.81
Pulmonary exposure to single-walled carbon nanotubes does not affect the early immune response against Toxoplasma gondii. Part Fibre Toxicol (2012) 0.80
Prevalence and risk factors of Toxoplasma gondii in fattening pigs farm from Yucatan, Mexico. Biomed Res Int (2013) 0.80
Performance Testing of PCR Assay in Blood Samples for the Diagnosis of Toxoplasmic Encephalitis in AIDS Patients from the French Departments of America and Genetic Diversity of Toxoplasma gondii: A Prospective and Multicentric Study. PLoS Negl Trop Dis (2016) 0.78
Recent developments in the interactions between caveolin and pathogens. Adv Exp Med Biol (2012) 0.78
Disposition of intravenous pyrimethamine in healthy volunteers. Antimicrob Agents Chemother (2000) 0.78
Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). Eur J Clin Microbiol Infect Dis (2011) 0.77
Carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase: biological activities and selective toxicities. Biochem Pharmacol (2010) 0.77
Hammondia hammondi harbors functional orthologs of the host-modulating effectors GRA15 and ROP16 but is distinguished from Toxoplasma gondii by a unique transcriptional profile. Eukaryot Cell (2014) 0.77
Focal Brain Lesions in People with HIV. Curr Treat Options Neurol (1999) 0.77
Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea. J Korean Med Sci (2010) 0.77
Molecular diagnosis of Toxoplasma gondii infection in Libya. BMC Infect Dis (2016) 0.77
Retracted Toxoplasmosis - An update. Trop Parasitol (2011) 0.76
Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis. Front Microbiol (2017) 0.76
1. In Vitro and In Vivo Activity of Sulfur-Containing Linear Bisphosphonates against Apicomplexan Parasites. Antimicrob Agents Chemother (2016) 0.75
Multiple intracerebral lesions in a young male. Afr Health Sci (2015) 0.75
Strength and Aerobic Physical Exercises Are Able to Increase Survival of Toxoplasma gondii-Infected C57BL/6 Mice by Interfering in the IFN-γ Expression. Front Physiol (2016) 0.75
Toxoplasma encephalitis and AIDS in a patient with seizure and altered mental status: A case report. World J Emerg Med (2017) 0.75
Toxoplasma encephalitis in an allogeneic hematopoietic stem cell transplant recipient in Korea. Korean J Intern Med (2012) 0.75
Trends, productivity losses, and associated medical conditions among toxoplasmosis deaths in the United States, 2000-2010. Am J Trop Med Hyg (2014) 0.75
Synergistic Activity between Statins and Bisphosphonates against Acute Experimental Toxoplasmosis. Antimicrob Agents Chemother (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med (1983) 11.15
Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J Clin Microbiol (1989) 5.26
Natural Distribution of the Ixodes dammini spirochete. Science (1983) 5.24
Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis (1993) 4.01
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Rapid capillary tube method for detecting penicillin resistance in Staphylococcus aureus. Appl Microbiol (1972) 3.58
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics (1999) 3.46
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Staphylococcus lugdunensis endocarditis. Lancet (1989) 3.21
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med (1997) 2.84
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med (1995) 2.63
Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med (1996) 2.58
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. Arch Intern Med (1993) 2.57
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group. AIDS (1997) 2.21
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
The geographic spread and temporal increase of the Lyme disease epidemic. JAMA (1991) 2.11
Fetal lung dysplasia: clinical outcome based on a new classification system. Ultrasound Obstet Gynecol (2004) 2.09
Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis (1997) 2.07
Comparison of muscle activity between conventional and neuromuscular splints. J Prosthet Dent (1993) 2.05
Evidence for a novel regulatory pathway for herpes simplex virus gene expression in trigeminal ganglion neurons. J Virol (1993) 2.01
Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr (2000) 1.98
Multiple infections of Ixodes scapularis ticks by Borrelia burgdorferi as revealed by single-strand conformation polymorphism analysis. J Clin Microbiol (1996) 1.94
Adult Ixodes dammini on rabbits: a hypothesis for the development and transmission of Borrelia burgdorferi. J Infect Dis (1987) 1.91
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
Interactions of phagocytes with the Lyme disease spirochete: role of the Fc receptor. J Infect Dis (1984) 1.88
Cost-effectiveness of alternative methods for diabetic retinopathy screening. Diabetes Care (1992) 1.86
Procedures associated with infective endocarditis in adults. A case control study. Eur Heart J (1995) 1.84
Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med (2001) 1.83
Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1993) 1.82
Screening for pregnancy risk-drinking. Alcohol Clin Exp Res (1994) 1.73
Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: case report and review of the literature. J Clin Microbiol (1988) 1.72
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials (2001) 1.71
Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin Infect Dis (1995) 1.70
Pyogenic and tuberculous spondylodiskitis (vertebral osteomyelitis) in 80 adult patients. Clin Infect Dis (1994) 1.69
Atrial tachyarrhythmia after cardiac surgery. Intensive Care Med (1998) 1.69
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med (1989) 1.68
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol (1991) 1.65
Mosquito-transmitted malaria in New York City, 1993. Lancet (1995) 1.63
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (2001) 1.63
A population genetic study of Borrelia burgdorferi sensu stricto from eastern Long Island, New York, suggested frequency-dependent selection, gene flow and host adaptation. Hereditas (1997) 1.60
Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. J Neurosurg (1999) 1.58
Selection of a cardiac surgery provider in the managed care era. J Thorac Cardiovasc Surg (2000) 1.58
Characteristics of infective endocarditis in France in 1991. A 1-year survey. Eur Heart J (1995) 1.57
Human and rodent hantavirus infection in New York State: public health significance of an emerging infectious disease. Arch Intern Med (1996) 1.53
Amblyomma americanum: a potential vector of Lyme disease in New Jersey. Science (1984) 1.53
Spirochete-associated arthritis (Lyme disease) in a dog. J Am Vet Med Assoc (1984) 1.52
Clinical and bacterial features of infections caused by Streptococcus milleri. Scand J Infect Dis (1991) 1.51
Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Am J Public Health (1996) 1.43
Antibiotic prophylaxis of late bacteremic vascular graft infection in a dog model. Ann Vasc Surg (1990) 1.41
Laser-assisted lead extraction: the European experience. Europace (2007) 1.41
Undiagnosed tuberculosis in patients with human immunodeficiency virus infection. Chest (1990) 1.41
Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med (2007) 1.40
Increased central body fat deposition precedes a significant rise in resting blood pressure in male offspring of essential hypertensive parents: a 5 year follow-up study. J Hypertens (2001) 1.40
[Surgical therapy of atrial fibrillation or: how much therapy is too much?]. Schweiz Med Wochenschr (1995) 1.40
[Zona in 50 patients infected by human immunodeficiency virus. Clinical manifestations and prognostic value]. Presse Med (1990) 1.40
Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet (1997) 1.39
Lithium for zidovudine-induced neutropenia in AIDS. JAMA (1989) 1.39
Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol (1990) 1.35
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab (1988) 1.33
Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev (2007) 1.32
Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol (1990) 1.28
Rattlesnake capsule-associated Salmonella arizona infections. Arch Intern Med (1988) 1.27
Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 1.27
Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother (2001) 1.24
Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet (1988) 1.21
Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review. Clin Infect Dis (1999) 1.21
Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.20
A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) Clin Infect Dis (1999) 1.20
Has the quality of serosurveillance in low- and middle-income countries improved since the last HIV estimates round in 2007? Status and trends through 2009. Sex Transm Infect (2010) 1.20
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med (1988) 1.17
Prevalence of the Lyme disease spirochete in populations of white-tailed deer and white-footed mice. Yale J Biol Med (1985) 1.15
Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. J Acquir Immune Defic Syndr (2001) 1.14
Definite streptococcus bovis endocarditis: characteristics in 20 patients. Clin Microbiol Infect (2001) 1.14
Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care (2004) 1.13
From the National Institutes of Health. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS. J Infect Dis (1991) 1.13
Pelvic instability after bone graft harvesting from posterior iliac crest: report of nine patients. Skeletal Radiol (2001) 1.13
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother (2000) 1.12
Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis (1993) 1.12
The prevalence and significance of Borrelia burgdorferi in the urine of feral reservoir hosts. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 1.11
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer (1996) 1.11
Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. Dig Dis Sci (1988) 1.11
Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect (2007) 1.11
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med (2000) 1.11
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr (2001) 1.10
In situ detection of PCR-amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and advanced-stage AIDS. J Acquir Immune Defic Syndr (1994) 1.09
Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Ann Epidemiol (1999) 1.09